ARCHIVES

New Biomarker Findings Show Improvement in KRAS Subtype In Phase III Erbitux Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 5 | May 30, 2014

Download PDF Visit The Full Archive

Related Articles

NCI To Offer Compromise On Including “Chop-Like Elements” In CCOP, Agrees Consortia “Appropriate”

May 14, 1982

NCI Advisors To Gain Increased Responsibility For Concept, Technical Merit Review Of Contracts

December 19, 1980

Scripps, Sandoz Deal Becomes Case Study As NI Rethinks Sponsored Research

January 28, 1994

Pinkel Corrects Report On ALL – Two Drugs Are Better Than One

April 21, 1978

FDA Deputy Commissioner Gottlieb To Return To AEI.

December 15, 2006

NCI To require Prompt Publication Of Data Affected By Falsification In Future Grants

April 8, 1994